Injectable Drug Delivery Devices Market By Product Type (Self-Injectors, Needle-Free, Auto Injectors, Wearable Injectors, Insulin Pens), By Drug Loading (Prefilled Injection Devices and Fillable Injection Device), By Reusability (Reusable and Disposable), Site Of Delivery (Intramuscular, Subcutaneous, Intra Dermal), By End User (Hospitals, Specialty Clinics, Homecare Settings), By Geography is expected to grow at a steady CAGR Forecast till 2027 owing to a Rise Observed in the demand for Self-Injectors and the Rise in Incidence of Chronic Conditions such as Cancer and Diabetes amongst others
Global Injectable Drug Delivery Devices Market was valued at USD 19.63 billion in 2021, growing at a CAGR of 11.26% during the forecast period from 2022 to 2027, to reach USD 37.22 billion by 2027. The demand for Injectable Drug Delivery Devices is primarily witnessing growth on account of the increasing incidences of chronic conditions such as cancer, diabetes and cardiovascular disorders among others, increase in demand for self-injectors, increase in biologics and biosimilar market, rising need and demand for patient compliance to treatment and the rising innovations and technological advancement in this arena.
The increasing incidences of chronic conditions such as cancer, diabetes and cardiovascular disorders among others is the major driving factor influencing the injectable drug delivery devices. According to the Cancer Journal for Clinicians 2021, on a worldwide basis an estimated 19.3 million new cancer cases and almost 10 million cancer deaths have taken place in the year 2020. As per the estimated of World Health Organization in 2019, cancer was the first or second leading cause of death before the age of 70 years in about 112 out of 183 countries and tends to rank third or fourth in further 23 countries.
As per the research paper “Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025” written by Lin et al. in 2020, in 2017, the global incidence, prevalence, death and disability adjusted life-years (DALYs) that were associated with diabetes were found to be 22.9 million, 476.0 million, 1.37 million, and 67.9 million, with a projection to 26.6 million, 570.9 million, 1.59 million, and 79.3 million in 2025, respectively.
Cardiovascular diseases are considered to be the leading cause of death globally. As per the World Health Organization in the year 2021, an estimated 17.9 million people died from cardiovascular disorders in 2019, illustrating 32% of all the global deaths. Out of the 17 million premature deaths (under the age of 70 years) due to non-communicable disease in 2019, 38% of the deaths were caused due to cardiovascular disorders.
Due to the rise in incidences of cancer, diabetes, cardiovascular disorders among other chronic conditions, there will be a rise observed in the chemotherapy and insulin delivery procedures and hence the increase in injectable drug delivery market.
However, certain side effects caused due to the nanoparticles of the drug delivery system and the high cost associated with advanced injectable drug delivery devices are expected to limit the market growth over the forecast period.
Injectable Drug Delivery Devices Market by Product Type (Self-Injectors, Needle-Free, Auto Injectors, Wearable Injectors and Insulin Pens), Injectable Drug Delivery Devices Market by Drug Loading (Prefilled Injection Devices and Fillable Injection Device), Injectable Drug Delivery Devices Market by Reusability (Reusable and Disposable), Site Of Delivery (Intramuscular, Subcutaneous and Intra Dermal), Injectable Drug Delivery Devices Market by End User (Hospitals, Specialty Clinics, Homecare Settings), and Injectable Drug Delivery Devices Market by Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the product type segment of the Injectable Drug Delivery Devices Market, self-injectors are likely to dominate the injectable drug delivery devices market. There have been innumerable innovations and developments that have taken place in this arena. Some profound advantages offered by self-injectors are they are extremely convenient for patient-use and are available at low costs. The product is built after patient feedback to expose patients with the most adaptable devices that can cater high precision of drug delivery and are easy to use. The preference for these device have lately increased among patients. Overall, the advantages offered by self-injectors and the awareness among patients for self-administration will lead to a surge in the market demand for these devices.
For instance, on October 21, 2019, Becton Dickinson had launched the two-step disposable autoinjector BD Intevia™, a robust platform device that combines autoinjector and pre-fillable syringe in an integrated system. The device was developed in order to promote patient ease of use when self-injecting.
Several technological advancements have led to an increased acceptance of self-injectors among patients. The use of liquefied gas, for instance liquefied hydrofluoroalkane (HFA), has acted as a power source presenting several advantages over the conventional spring-based injectors. The major advantage is that it tends to offer a constant force over the duration of injection. In order to achieve full injection, the HFA-powered autoinjectors tend to require lower peaks forces when compared with the typical spring autoinjector because the force does not tend to decay. This applies lower stresses on the syringe and results in lower variation of force during drug delivery. Due to the various advantages offered by self-injectors in contrast to other product types, there will be an increase in demand among the patients for these, hence leading to a surge in the self-injector market.
Among all the regions, North America is expected to account for the largest share in the injectable drug delivery devices market. This can be attributed to the rising numbers of chronic diseases, increasing research and developments, government initiatives in order to increase awareness about the chronic conditions and the rise in healthcare spending are predicted to be the major influencing factors in driving the overall growth of the market over the forecast period.
According to the Cancer Facts and Figures 2020, there will be around 89,500 cancer cases being diagnosed and about 9,270 cancer deaths in adolescents and young adults that are in between the age of 15 to 39 in United States. According to the Cancer Statistics by National Cancer Institute, in 2020 an estimated 1,806,590 new cases of cancer that have been diagnosed in the United States and 606,520 people have died from the disease. Prostrate lung cancers, colorectal cancers and lung cancers have been 43% of all the cancers diagnosed amongst men in the year 2020. Due to the rising number of chronic conditions such as cancers, there will be a surge observed in chemotherapy procedures and hence the market for drug delivery devices is expected to rise.
According to the heart disease facts, updated in 2020, coronary disease is the most common type of heart disease killing approximately 365,914 people in the year 2017. In United States, someone is suffering from a heart attack every 40 seconds. The rising number of chronic conditions is ultimately leading to an increased rate of drug delivery using injectable drug delivery devices, thus helping in driving the Injectable Drug Delivery Devices Market.
Increasing research and development that has resulting in huge technological advancements, thereby the insulin manufacturers are trying to replace their injection pen devices with those that are well-equipped with advanced features such as the digital dose memory and recording, comprising new dosing mechanisms and a user friendly design interface which allows easier dose dialing or a lower force for delivering the drug.
Some of the key market players operating in the Injectable Drug Delivery Devices market includes Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, Emperra GmbH, Gerresheimer AG, SCHOTT AG, Terumo Corporation and others.
What is Injectable Drug Delivery Devices?
Injectable Drug Delivery devices comprise of self-injectors, needle-free, auto injectors and others. These devices help in drug delivery at targeted areas in the body. The devices tend to allow patients for easier administration of drugs without the need of any medical assistance.
What is the market for Global Injectable Drug Delivery Devices?
Global Injectable Drug Delivery Devices Market was valued at USD 19.63 billion in 2021, growing at a CAGR of 11.26% during the forecast period from 2022 to 2027, to reach USD 37.22 billion by 2027.
What are the drivers for Global Injectable Drug Delivery Devices?
The major drivers driving the demand for Injectable Drug Delivery Devices are the rising incidences of chronic conditions, for instance the cancer, diabetes and cardiovascular disorders among others, an increase in the demand for self-injectors, rise in biologics and biosimilar market and the increasing need and demand for patient compliance to treatment and the rising innovations and technological advancement in this arena.
What are the key players operating in Global Injectable Drug Delivery Devices?
Some of the key market players operating in the Injectable Drug Delivery Devices market includes Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, and others.
What regions has the highest share in Injectable Drug Delivery Devices market?
North America is expected to dominate the overall Injectable Drug Delivery Devices market during the forecast period, 2022 to 2027. This domination is due to the increasing numbers of chronic diseases, rising research and developments, and increasing government initiatives in order to improve awareness about the chronic conditions and the rise in healthcare spending.
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.
Global Injectable Drug Delivery Devices Market was valued at USD 19.63 billion in 2021, growing at a CAGR of 11.26% during the forecast period from 2022 to 2027, to reach USD 37.22 billion by 2027. The demand for Injectable Drug Delivery Devices is primarily witnessing growth on account of the increasing incidences of chronic conditions such as cancer, diabetes and cardiovascular disorders among others, increase in demand for self-injectors, increase in biologics and biosimilar market, rising need and demand for patient compliance to treatment and the rising innovations and technological advancement in this arena.
Injectable Drug Delivery Devices Market Dynamics:
The increasing incidences of chronic conditions such as cancer, diabetes and cardiovascular disorders among others is the major driving factor influencing the injectable drug delivery devices. According to the Cancer Journal for Clinicians 2021, on a worldwide basis an estimated 19.3 million new cancer cases and almost 10 million cancer deaths have taken place in the year 2020. As per the estimated of World Health Organization in 2019, cancer was the first or second leading cause of death before the age of 70 years in about 112 out of 183 countries and tends to rank third or fourth in further 23 countries.
As per the research paper “Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025” written by Lin et al. in 2020, in 2017, the global incidence, prevalence, death and disability adjusted life-years (DALYs) that were associated with diabetes were found to be 22.9 million, 476.0 million, 1.37 million, and 67.9 million, with a projection to 26.6 million, 570.9 million, 1.59 million, and 79.3 million in 2025, respectively.
Cardiovascular diseases are considered to be the leading cause of death globally. As per the World Health Organization in the year 2021, an estimated 17.9 million people died from cardiovascular disorders in 2019, illustrating 32% of all the global deaths. Out of the 17 million premature deaths (under the age of 70 years) due to non-communicable disease in 2019, 38% of the deaths were caused due to cardiovascular disorders.
Due to the rise in incidences of cancer, diabetes, cardiovascular disorders among other chronic conditions, there will be a rise observed in the chemotherapy and insulin delivery procedures and hence the increase in injectable drug delivery market.
However, certain side effects caused due to the nanoparticles of the drug delivery system and the high cost associated with advanced injectable drug delivery devices are expected to limit the market growth over the forecast period.
Injectable Drug Delivery Devices Market Segment Analysis:
Injectable Drug Delivery Devices Market by Product Type (Self-Injectors, Needle-Free, Auto Injectors, Wearable Injectors and Insulin Pens), Injectable Drug Delivery Devices Market by Drug Loading (Prefilled Injection Devices and Fillable Injection Device), Injectable Drug Delivery Devices Market by Reusability (Reusable and Disposable), Site Of Delivery (Intramuscular, Subcutaneous and Intra Dermal), Injectable Drug Delivery Devices Market by End User (Hospitals, Specialty Clinics, Homecare Settings), and Injectable Drug Delivery Devices Market by Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the product type segment of the Injectable Drug Delivery Devices Market, self-injectors are likely to dominate the injectable drug delivery devices market. There have been innumerable innovations and developments that have taken place in this arena. Some profound advantages offered by self-injectors are they are extremely convenient for patient-use and are available at low costs. The product is built after patient feedback to expose patients with the most adaptable devices that can cater high precision of drug delivery and are easy to use. The preference for these device have lately increased among patients. Overall, the advantages offered by self-injectors and the awareness among patients for self-administration will lead to a surge in the market demand for these devices.
For instance, on October 21, 2019, Becton Dickinson had launched the two-step disposable autoinjector BD Intevia™, a robust platform device that combines autoinjector and pre-fillable syringe in an integrated system. The device was developed in order to promote patient ease of use when self-injecting.
Several technological advancements have led to an increased acceptance of self-injectors among patients. The use of liquefied gas, for instance liquefied hydrofluoroalkane (HFA), has acted as a power source presenting several advantages over the conventional spring-based injectors. The major advantage is that it tends to offer a constant force over the duration of injection. In order to achieve full injection, the HFA-powered autoinjectors tend to require lower peaks forces when compared with the typical spring autoinjector because the force does not tend to decay. This applies lower stresses on the syringe and results in lower variation of force during drug delivery. Due to the various advantages offered by self-injectors in contrast to other product types, there will be an increase in demand among the patients for these, hence leading to a surge in the self-injector market.
North America is expected to dominate the overall Injectable Drug Delivery Devices Market:
Among all the regions, North America is expected to account for the largest share in the injectable drug delivery devices market. This can be attributed to the rising numbers of chronic diseases, increasing research and developments, government initiatives in order to increase awareness about the chronic conditions and the rise in healthcare spending are predicted to be the major influencing factors in driving the overall growth of the market over the forecast period.
According to the Cancer Facts and Figures 2020, there will be around 89,500 cancer cases being diagnosed and about 9,270 cancer deaths in adolescents and young adults that are in between the age of 15 to 39 in United States. According to the Cancer Statistics by National Cancer Institute, in 2020 an estimated 1,806,590 new cases of cancer that have been diagnosed in the United States and 606,520 people have died from the disease. Prostrate lung cancers, colorectal cancers and lung cancers have been 43% of all the cancers diagnosed amongst men in the year 2020. Due to the rising number of chronic conditions such as cancers, there will be a surge observed in chemotherapy procedures and hence the market for drug delivery devices is expected to rise.
According to the heart disease facts, updated in 2020, coronary disease is the most common type of heart disease killing approximately 365,914 people in the year 2017. In United States, someone is suffering from a heart attack every 40 seconds. The rising number of chronic conditions is ultimately leading to an increased rate of drug delivery using injectable drug delivery devices, thus helping in driving the Injectable Drug Delivery Devices Market.
Increasing research and development that has resulting in huge technological advancements, thereby the insulin manufacturers are trying to replace their injection pen devices with those that are well-equipped with advanced features such as the digital dose memory and recording, comprising new dosing mechanisms and a user friendly design interface which allows easier dose dialing or a lower force for delivering the drug.
Injectable Drug Delivery Devices Market Key Players:
Some of the key market players operating in the Injectable Drug Delivery Devices market includes Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, Emperra GmbH, Gerresheimer AG, SCHOTT AG, Terumo Corporation and others.
Recent Developmental Activities in Injectable Drug Delivery Devices Market:
- On August 21, 2021, Zydus Cadila's needle-free, plasmid DNA Covid vaccine had received the Drug Controller General of India (DCGI) approval.
- On November 13, 2019, Stevanato and Duoject had entered auto-injector collaboration for manufacturing and promoting the emergency use ‘Maverick' auto-injector.
- On October 21, 2019, Becton Dickinson and Company, a leading global medical technology company had announced the launch of BD Intevia™ 1mL two-step disposable autoinjector, a robust platform device combining autoinjector and pre-fillable syringe in one integrated system.
- Market size analysis for current market size (2021), and market forecast for 5 years (2022-2027)
- The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the market.
- Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
- Key companies dominating the Global Injectable Drug Delivery Devices Market.
- Various opportunities available for the other competitor in the Injectable Drug Delivery Devices Market space.
- What are the top performing segments in 2021? How these segments will perform in 2027?
- Which is the top-performing regions and countries in the current market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for market growth in the coming future?
Target Audience who can be benefited from the Injectable Drug Delivery Devices Market Report Study
- Injectable Drug Delivery Devices providers
- Research organizations and consulting companies
- Injectable Drug Delivery Devices-related organization, association, forum, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and Traders
- Various End-users who want to know more about the Injectable Drug Delivery Devices Market and latest technological developments in the Injectable Drug Delivery Devices market.
Frequently Asked Questions for Injectable Drug Delivery Devices Market:
What is Injectable Drug Delivery Devices?
Injectable Drug Delivery devices comprise of self-injectors, needle-free, auto injectors and others. These devices help in drug delivery at targeted areas in the body. The devices tend to allow patients for easier administration of drugs without the need of any medical assistance.
What is the market for Global Injectable Drug Delivery Devices?
Global Injectable Drug Delivery Devices Market was valued at USD 19.63 billion in 2021, growing at a CAGR of 11.26% during the forecast period from 2022 to 2027, to reach USD 37.22 billion by 2027.
What are the drivers for Global Injectable Drug Delivery Devices?
The major drivers driving the demand for Injectable Drug Delivery Devices are the rising incidences of chronic conditions, for instance the cancer, diabetes and cardiovascular disorders among others, an increase in the demand for self-injectors, rise in biologics and biosimilar market and the increasing need and demand for patient compliance to treatment and the rising innovations and technological advancement in this arena.
What are the key players operating in Global Injectable Drug Delivery Devices?
Some of the key market players operating in the Injectable Drug Delivery Devices market includes Eli Lilly and Company, Biocon, Becton, Dickinson & Company, West Pharmaceutical Services, Inc., Johnson & Johnson, Antares Pharma, AbbVie Inc., Pfizer Inc., Mylan N.V., Vetter Pharma-Fertigung GmbH & Co.KG, and others.
What regions has the highest share in Injectable Drug Delivery Devices market?
North America is expected to dominate the overall Injectable Drug Delivery Devices market during the forecast period, 2022 to 2027. This domination is due to the increasing numbers of chronic diseases, rising research and developments, and increasing government initiatives in order to improve awareness about the chronic conditions and the rise in healthcare spending.
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.
Table of Contents
1. Injectable Drug Delivery Devices Report Introduction2. Injectable Drug Delivery Devices Executive summary
2.1 Scope of the Study
2.2 Market at Glance
2.3 Competitive Assessment
2.4 Financial Benchmarking
3. Regulatory and Patent Analysis
3.1 The United States
3.2 Europe
3.2.1 Germany
3.2.2 France
3.2.3 Italy
3.2.4 Spain
3.2.5 U.K.
3.3 Japan
4 Injectable Drug Delivery Devices Key Factors Analysis
4.1 Injectable Drug Delivery Devices Market Drivers
4.1.1 Increasing incidences of chronic conditions such as cancer, diabetes and cardiovascular disorders among others
4.1.2 Increase in demand for self-injectors
4.1.3 Increase in biologics and biosimilar market
4.1.4 Rising need and demand for patient compliance to treatment
4.1.5 Rising innovations and technological advancement
4.2 Injectable Drug Delivery Devices Market Restraints and Challenges
4.2.1 Certain side effects caused due to the nanoparticles of the drug delivery system
4.2.2 High cost associated with advanced injectable drug delivery devices are expected to limit the market growth over the forecast period.
4.3 Injectable Drug Delivery Devices Market Opportunities
4.3.1 The increasing awareness among elderly people has also increased the demand for connected injectable drug delivery devices
4.3.2 Rising demand for disposable injecting devices and prefilled syringes
5 Injectable Drug Delivery Devices Porter's Five Forces Analysis
5.1 Bargaining Power of Suppliers
5.2 Bargaining Power of Consumers
5.3 Threat of New Entrants
5.4 Threat of Substitutes
5.5 Competitive Rivalry
6 COVID-19 Impact Analysis on Injectable Drug Delivery Devices Market
7. Injectable Drug Delivery Devices Market Layout
7.1 By Reusability
7.1.1 Reusable Devices
7.1.2 Disposable Devices
7.2 By On Site Delivery
7.2.1 Intramuscular
7.2.2 Intradermal
7.2.3 Subcutaneous
7.3 By Product Type
7.3.1 Self-injectors
7.3.2 Needle-free Injectors
7.3.3 Auto Injectors
7.3.4 Wearable Injectors
7.3.5 Insulin Pens
7.4 By Drug Loading
7.4.1 Pre filled devices
7.4.2 Fillable Devices
7.5 By End User
7.5.1 Hospitals
7.5.2 Specialty Clinics
7.5.3 Home care settings
7.6 By Geography
7.6.1 North America
7.6.1.1 North America Injectable Drug Delivery Devices Market, by Product Type
7.6.1.2 North America Injectable Drug Delivery Devices Market, by On Site Delivery
7.6.1.3 North America Injectable Drug Delivery Devices Market, by Drug Loading
7.6.1.4 North America Injectable Drug Delivery Devices Market, by End User
7.6.1.5 North America Injectable Drug Delivery Devices Market, by Reusability
7.6.1.6 North America Injectable Drug Delivery Devices Market, by Country
7.6.1.6.1 United States
7.6.1.6.2 Canada
7.6.1.6.3 Mexico
7.6.2 Europe
7.6.2.1 Europe Injectable Drug Delivery Devices Market, by Product Type
7.6.2.2 Europe Injectable Drug Delivery Devices Market, by End User
7.6.2.3 Europe Injectable Drug Delivery Devices Market, by On Site Delivery
7.6.2.4 Europe Injectable Drug Delivery Devices Market, by Reusability
7.6.2.5 Europe Injectable Drug Delivery Devices Market, by Drug Loading
7.6.2.6 Europe Injectable Drug Delivery Devices Market, by Country
7.6.2.6.1 France
7.6.2.6.2 Germany
7.6.2.6.3 United Kingdom
7.6.2.6.4 Italy
7.6.2.6.5 Spain
7.6.2.6.6 Russia
7.6.2.6.7 Rest of Europe
7.6.3 Asia-Pacific
7.6.3.1 Asia-Pacific Injectable Drug Delivery Devices Market, by Product Type
7.6.3.2 Asia-Pacific Injectable Drug Delivery Devices Market, by End User
7.6.3.3 Asia-Pacific Injectable Drug Delivery Devices Market, by On Site Delivery
7.6.3.4 Asia-Pacific Injectable Drug Delivery Devices Market, by Reusability
7.6.3.5 Asia-Pacific Injectable Drug Delivery Devices Market, by Drug Loading
7.6.3.6 Asia-Pacific Injectable Drug Delivery Devices Market, by Country
7.6.3.6.1 China
7.6.3.6.2 Japan
7.6.3.6.3 India
7.6.3.6.4 Australia
7.6.3.6.5 South Korea
7.6.3.6.6 Rest of Asia Pacific
7.6.4 Rest of the World (RoW)
7.6.4.1 RoW Injectable Drug Delivery Devices Market, by Product Type
7.6.4.2 RoW Injectable Drug Delivery Devices Market, by End User
7.6.4.3 RoW Injectable Drug Delivery Devices Market, by Reusability
7.6.4.4 RoW Injectable Drug Delivery Devices Market, by On Site Delivery
7.6.4.5 RoW Injectable Drug Delivery Devices Market, by Drug Loading
7.6.4.6 RoW Injectable Drug Delivery Devices Market, by Region
7.6.4.6.1 Middle East
7.6.4.6.2 Africa
7.6.4.6.3 South America
8. Injectable Drug Delivery Devices Global Company Share Analysis - Key 3-5 Companies
9. Injectable Drug Delivery Devices Company and Product Profiles
9.1 Eli Lilly and Company
9.1.1. Company Overview
9.1.2. Company Snapshot
9.1.3. Financial Overview
9.1.4 Product Listing
9.1.5. Entropy
9.2 Biocon
9.2.1. Company Overview
9.2.2. Company Snapshot
9.2.3. Financial Overview
9.2.4 Product Listing
9.2.5. Entropy
9.3 Becton, Dickinson & Company
9.3.1. Company Overview
9.3.2. Company Snapshot
9.3.3. Financial Overview
9.3.4 Product Listing
9.3.5. Entropy
9.4 West Pharmaceutical Services, Inc.
9.4.1. Company Overview
9.4.2. Company Snapshot
9.4.3. Financial Overview
9.4.4 Product Listing
9.4.5. Entropy
9.5 Johnson & Johnson
9.5.1. Company Overview
9.5.2. Company Snapshot
9.5.3. Financial Overview
9.5.4 Product Listing
9.5.5. Entropy
9.6 Antares Pharma
9.6.1. Company Overview
9.6.2. Company Snapshot
9.6.3. Financial Overview
9.6.4 Product Listing
9.6.5. Entropy
9.7 AbbVie Inc.
9.7.1. Company Overview
9.7.2. Company Snapshot
9.7.3. Financial Overview
9.7.4 Product Listing
9.7.5. Entropy
9.8 Pfizer Inc.
9.8.1. Company Overview
9.8.2. Company Snapshot
9.8.3. Financial Overview
9.8.4 Product Listing
9.8.5. Entropy
9.9 Mylan N.V.
9.9.1. Company Overview
9.9.2. Company Snapshot
9.9.3. Financial Overview
9.9.4 Product Listing
9.9.5. Entropy
9.10 Vetter Pharma-Fertigung GmbH & Co.KG
9.10.1. Company Overview
9.10.2. Company Snapshot
9.10.3. Financial Overview
9.10.4 Product Listing
9.10.5. Entropy
9.11 Emperra GmbH
9.11.1. Company Overview
9.11.2. Company Snapshot
9.11.3. Financial Overview
9.11.4 Product Listing
9.11.5. Entropy
9.12 Gerresheimer AG
9.12.1. Company Overview
9.12.2. Company Snapshot
9.12.3. Financial Overview
9.12.4 Product Listing
9.12.5. Entropy
9.13 SCHOTT AG
9.13.1. Company Overview
9.13.2. Company Snapshot
9.13.3. Financial Overview
9.13.4 Product Listing
9.13.5. Entropy
9.14 Terumo Corporation
9.14.1. Company Overview
9.14.2. Company Snapshot
9.14.3. Financial Overview
9.14.4 Product Listing
9.14.5. Entropy
9.15 Teva Pharmaceutical Industries Ltd
9.15.1. Company Overview
9.15.2. Company Snapshot
9.15.3. Financial Overview
9.15.4 Product Listing
9.15.5. Entropy
10. PROJECT APPROACH
10.1 Secondary Sources
10.2 Primary Sources
10.3 Data Triangulation
10.4 Key Expert Opinions
11. KOL Views
12. Publisher Capabilities
13. Disclaimer
14. About the PublisherList of Tables
Table 1 Competitive Analysis
Table 2 COVID-19 Impact Analysis
Table 3 Injectable Drug Delivery Devices in Global (2019-2027)
Table 4 Injectable Drug Delivery Devices in Global by Product Type (2019-2027)
Table 5 Injectable Drug Delivery Devices in Global by Reusability (2019-2027)
Table 6 Injectable Drug Delivery Devices in Global by Drug Loading (2019-2027)
Table 7 Injectable Drug Delivery Devices in Global by On Site Delivery (2019-2027)
Table 8 Injectable Drug Delivery Devices in Global by End User (2019-2027)
Table 9 Injectable Drug Delivery Devices in Global by Geography (2019-2027)
Table 10 Injectable Drug Delivery Devices in North America (2019-2027)
Table 11 Injectable Drug Delivery Devices in North America by Product Type (2019-2027)
Table 12 Injectable Drug Delivery Devices in North America by Reusability (2019-2027)
Table 13 Injectable Drug Delivery Devices in North America by Drug Loading (2019-2027)
Table 14 Injectable Drug Delivery Devices in North America by On Site Delivery (2019-2027)
Table 15 Injectable Drug Delivery Devices in North America by End User (2019-2027)
Table 16 Injectable Drug Delivery Devices in North America by Country (2019-2027)
Table 17 Injectable Drug Delivery Devices in the US (2019-2027)
Table 18 Injectable Drug Delivery Devices in Canada (2019-2027)
Table 19 Injectable Drug Delivery Devices in Mexico (2019-2027)
Table 20 Injectable Drug Delivery Devices in Europe (2019-2027)
Table 21 Injectable Drug Delivery Devices in Europe by Product Type (2019-2027)
Table 22 Injectable Drug Delivery Devices in Europe by Reusability (2019-2027)
Table 23 Injectable Drug Delivery Devices in Europe by Drug Loading (2019-2027)
Table 24 Injectable Drug Delivery Devices in Europe by On Site Delivery (2019-2027)
Table 25 Injectable Drug Delivery Devices in Europe by End User (2019-2027)
Table 26 Injectable Drug Delivery Devices in Europe by Country (2019-2027)
Table 27 Injectable Drug Delivery Devices in France (2019-2027)
Table 28 Injectable Drug Delivery Devices in Germany (2019-2027)
Table 29 Injectable Drug Delivery Devices in UK (2019-2027)
Table 30 Injectable Drug Delivery Devices in Italy (2019-2027)
Table 31 Injectable Drug Delivery Devices in Spain (2019-2027)
Table 32 Injectable Drug Delivery Devices in Russia (2019-2027)
Table 33 Injectable Drug Delivery Devices in Rest of Europe (2019-2027)
Table 34 Injectable Drug Delivery Devices in Asia Pacific (2019-2027)
Table 35 Injectable Drug Delivery Devices in Asia Pacific by Product Type (2019-2027)
Table 36 Injectable Drug Delivery Devices in Asia Pacific by Reusability (2019-2027)
Table 37 Injectable Drug Delivery Devices in Asia Pacific by Drug Loading (2019-2027)
Table 38 Injectable Drug Delivery Devices in Asia Pacific by On Site Delivery (2019-2027)
Table 39 Injectable Drug Delivery Devices in Asia Pacific by End User (2019-2027)
Table 40 Injectable Drug Delivery Devices in Asia Pacific by Country (2019-2027)
Table 41 Injectable Drug Delivery Devices in China (2019-2027)
Table 42 Injectable Drug Delivery Devices in Japan (2019-2027)
Table 43 Injectable Drug Delivery Devices in India (2019-2027)
Table 44 Injectable Drug Delivery Devices in Australia (2019-2027)
Table 45 Injectable Drug Delivery Devices in South Korea (2019-2027)
Table 46 Injectable Drug Delivery Devices in Rest of Asia Pacific (2019-2027)
Table 47 Injectable Drug Delivery Devices in Rest of the World (2019-2027)
Table 48 Injectable Drug Delivery Devices in Rest of the World by Product Type (2019-2027)
Table 49 Injectable Drug Delivery Devices in Rest of the World by Reusability (2019-2027)
Table 50 Injectable Drug Delivery Devices in Rest of the World by Drug Loading (2019-2027)
Table 51 Injectable Drug Delivery Devices in Rest of the World by On Site Delivery (2019-2027)
Table 52 Injectable Drug Delivery Devices in Rest of the World by End User (2019-2027)
Table 53 Injectable Drug Delivery Devices in Rest of the World by Country (2019-2027)
Table 54 Injectable Drug Delivery Devices in Middle East (2019-2027)
Table 55 Injectable Drug Delivery Devices in Africa (2019-2027)
Table 56 Injectable Drug Delivery Devices in South America (2019-2027)List of Figures
Figure 1 Competitive Analysis
Figure 2 COVID-19 Impact Analysis
Figure 3 Injectable Drug Delivery Devices in Global (2019-2027)
Figure 4 Injectable Drug Delivery Devices in Global by Product Type (2019-2027)
Figure 5 Injectable Drug Delivery Devices in Global by Reusability (2019-2027)
Figure 6 Injectable Drug Delivery Devices in Global by Drug Loading (2019-2027)
Figure 7 Injectable Drug Delivery Devices in Global by On Site Delivery (2019-2027)
Figure 8 Injectable Drug Delivery Devices in Global by End User (2019-2027)
Figure 9 Injectable Drug Delivery Devices in Global by Geography (2019-2027)
Figure 10 Injectable Drug Delivery Devices in North America (2019-2027)
Figure 11 Injectable Drug Delivery Devices in North America by Product Type (2019-2027)
Figure 12 Injectable Drug Delivery Devices in North America by Reusability (2019-2027)
Figure 13 Injectable Drug Delivery Devices in North America by Drug Loading (2019-2027)
Figure 14 Injectable Drug Delivery Devices in North America by On Site Delivery (2019-2027)
Figure 15 Injectable Drug Delivery Devices in North America by End User (2019-2027)
Figure 16 Injectable Drug Delivery Devices in North America by Country (2019-2027)
Figure 17 Injectable Drug Delivery Devices in the US (2019-2027)
Figure 18 Injectable Drug Delivery Devices in Canada (2019-2027)
Figure 19 Injectable Drug Delivery Devices in Mexico (2019-2027)
Figure 20 Injectable Drug Delivery Devices in Europe (2019-2027)
Figure 21 Injectable Drug Delivery Devices in Europe by Product Type (2019-2027)
Figure 22 Injectable Drug Delivery Devices in Europe by Reusability (2019-2027)
Figure 23 Injectable Drug Delivery Devices in Europe by Drug Loading (2019-2027)
Figure 24 Injectable Drug Delivery Devices in Europe by On Site Delivery (2019-2027)
Figure 25 Injectable Drug Delivery Devices in Europe by End User (2019-2027)
Figure 26 Injectable Drug Delivery Devices in Europe by Country (2019-2027)
Figure 27 Injectable Drug Delivery Devices in France (2019-2027)
Figure 28 Injectable Drug Delivery Devices in Germany (2019-2027)
Figure 29 Injectable Drug Delivery Devices in UK (2019-2027)
Figure 30 Injectable Drug Delivery Devices in Italy (2019-2027)
Figure 31 Injectable Drug Delivery Devices in Spain (2019-2027)
Figure 32 Injectable Drug Delivery Devices in Russia (2019-2027)
Figure 33 Injectable Drug Delivery Devices in Rest of Europe (2019-2027)
Figure 34 Injectable Drug Delivery Devices in Asia Pacific (2019-2027)
Figure 35 Injectable Drug Delivery Devices in Asia Pacific by Product Type (2019-2027)
Figure 36 Injectable Drug Delivery Devices in Asia Pacific by Reusability (2019-2027)
Figure 37 Injectable Drug Delivery Devices in Asia Pacific by Drug Loading (2019-2027)
Figure 38 Injectable Drug Delivery Devices in Asia Pacific by On Site Delivery (2019-2027)
Figure 39 Injectable Drug Delivery Devices in Asia Pacific by End User (2019-2027)
Figure 40 Injectable Drug Delivery Devices in Asia Pacific by Country (2019-2027)
Figure 41 Injectable Drug Delivery Devices in China (2019-2027)
Figure 42 Injectable Drug Delivery Devices in Japan (2019-2027)
Figure 43 Injectable Drug Delivery Devices in India (2019-2027)
Figure 44 Injectable Drug Delivery Devices in Australia (2019-2027)
Figure 45 Injectable Drug Delivery Devices in South Korea (2019-2027)
Figure 46 Injectable Drug Delivery Devices in Rest of Asia Pacific (2019-2027)
Figure 47 Injectable Drug Delivery Devices in Rest of the World (2019-2027)
Figure 48 Injectable Drug Delivery Devices in Rest of the World by Product Type (2019-2027)
Figure 49 Injectable Drug Delivery Devices in Rest of the World by Reusability (2019-2027)
Figure 50 Injectable Drug Delivery Devices in Rest of the World by Drug Loading (2019-2027)
Figure 51 Injectable Drug Delivery Devices in Rest of the World by On Site Delivery (2019-2027)
Figure 52 Injectable Drug Delivery Devices in Rest of the World by End User (2019-2027)
Figure 53 Injectable Drug Delivery Devices in Rest of the World by Country (2019-2027)
Figure 54 Injectable Drug Delivery Devices in Middle East (2019-2027)
Figure 55 Injectable Drug Delivery Devices in Africa (2019-2027)
Figure 56 Injectable Drug Delivery Devices in South America (2019-2027)
Figure 57 Market Drivers
Figure 58 Market Barriers
Figure 59 Market Opportunities
Figure 60 PORTER'S Five Force Analysis
